Date: April 25th, 2022 Your Name: Monika Vidlarova Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
	medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133]	Institutional funding
		Palacky University Olomouc [LF 2021_019]	Institutional funding
		Technological Agency of the Czech Republic [TN01000013]	Institutional funding
		European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102)	Institutional funding

		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133], Palacky University Olomouc [LF 2021_019], Technological Agency of the Czech Republic [TN01000013] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102). Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Emil Berta Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
	medical writing, article	Ministry of Education,	Institutional funding
	processing charges, etc.)	Youth and Sport of the	
	No time limit for this item.	Czech Republic	
		[LM2018125, LM2018133]	
		European Union - Next	Institutional funding
		Generation EU	
		(Programme EXCELES, ID	
		Project No. LX22NPO5102)	
		Time frame: past	36 months
2	Grants or contracts from	None	
2	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
	5		
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	,		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Dessist of any immediate	Neze	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133],] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102).

Please place an "X" next to the following statement to indicate your agreement:

Date: 24.04.2022 Your Name: Petr Prasil Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470].

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Andrea Prokopova Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present		
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date: April 28, 2022 Your Name: Soňa Gurská Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
	medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133]	Institutional funding
		Palacky University Olomouc [LF 2021 019]	Institutional funding
		Technological Agency of the Czech Republic [TN01000013]	Institutional funding
		European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102)	Institutional funding

		Time fromer next 20 menths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past 36 monthsNoneNoneNone
3	Royalties or licenses	None
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133], Palacky University Olomouc [LF 2021_019], Technological Agency of the Czech Republic [TN01000013] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102). Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Marta Khoylu Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

Time	e frame: Since the initial planni	none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institutior
1	All support for the manuscript (e.g., funding, pr of study materials, medical article processing charges, etc No time limit for this item.	Ministry of Health of the Republic [NV18-03-00470] Ministry of Education, You	Institutional funding Institutional funding
Time	e frame: past 36 months		
2	Grants or contracts from any e not indicated in item #1 above		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for le	None	
	presentations, speakers b		
	manuscript writing or edu		
	events		
6	Payment for expert testimony	None	
7	Support for attending m and/or travel	None	
8	Patents planned, issued or pe	None	
9	Participation on a Data	None	
	Safety Monitoring Board or A		
	Board		
10	Leadership or fiduciary role i		
	board, society, committe		
	advocacy group, paid or unpa		
11	Stock or stock options	_None	
12	Receipt of equipment, ma		
	drugs, medical writing, gifts o	1	
	services		
13	Other financial or non-f	None	
	interests		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102).

Please place an "X" next to the following statement to indicate your agreement:

Date: May 5, 2022 Your Name: Alona Rehulkova Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with whor have this relationship or ine none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution
Time	e frame: Since the initial planni	ng of the work	
1	All support for the pr manuscript (e.g., funding, pro	Ministry of Health of the Republic [NV18-03-00470]	Institutional funding
	of study materials, medical w article processing charges, etc	-	-
	No time limit for this item.	[LM2018125, LM2018133]	
		Palacky University Olomou 2021_019]	Institutional funding
		Technological Agency of the Republic [TN01000013]	Institutional funding
		European Union - Next Gene EU (Programme EXCELES Project No. LX22NPO5102)	-
Time	e frame: past 36 months		
2		None	

	Grants or contracts from any (if not indicated in item #1 abo		
3	Royalties or licenses	None	
4	Consulting fees	None	
-		Mara a	
5	Payment or honoraria for lec presentations, speakers bu		
	manuscript writing or educa		
	events		
6	Payment for expert testimony	None	
7	Support for attending me and/or travel	None	
8	Patents planned, issued or per	None	
		••	
9	Participation on a Data Safety Monitoring Board	None	
	Advisory Board		
10	Leadership or fiduciary role in	None	
	board, society, committee		
	advocacy group, paid or unpai		
11	Stock or stock options	None	
12	Receipt of equipment, mat		
	drugs, medical writing, gifts or services		
13	Other financial or non-fin	None	
15	interests		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133], Palacky University Olomouc [LF 2021_019], Technological Agency of the Czech Republic [TN01000013] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102). Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Pavla Kourilova Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
	medical writing, article	Ministry of Education,	Institutional funding
	processing charges, etc.)	Youth and Sport of the	
	No time limit for this item.	Czech Republic	
		[LM2018125, LM2018133]	
		European Union - Next	Institutional funding
		Generation EU	
		(Programme EXCELES, ID	
		Project No. LX22NPO5102)	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or	_	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102).

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Josef Chudacek Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
-			
7	Support for attending meetings and/or travel	None	
	incerings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nene	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	None	
13	other financial or non-		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470].

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Marek Szkorupa Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
-			
7	Support for attending meetings and/or travel	None	
	incerings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nene	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	None	
13	other financial or non-		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470].

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Jiri Klein Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
4	consulting rees	None	
5	Payment or honoraria for	None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
Ŭ	testimony		
	cestimony		
7	Support for attending	None	
	meetings and/or travel		
	Deterrite allowed issued on	News	
8	Patents planned, issued or	None	
	pending		
0			
9	Participation on a Data	None	
	Safety Monitoring Board or		
- 10	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11			
12	Receipt of equipment,	None	
12	materials, drugs, medical		
1	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470].

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Jozef Skarda Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
-			
7	Support for attending meetings and/or travel	None	
	incerings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nene	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	None	
13	other financial or non-		

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470].

Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Josef Srovnal Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials,	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding		
	medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133]	Institutional funding		
		Palacky University Olomouc [LF 2021_019]	Institutional funding		
		Technological Agency of the Czech Republic [TN01000013]	Institutional funding		
		European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102)	Institutional funding		
		Cancer Research Czech Republic	Institutional funding		

	Time frame: past 36 months						
2	Grants or contracts from	None					
	any entity (if not indicated in item #1 above).						
2	•	None					
3	Royalties or licenses						
4	Consulting fees	None					
-							
5	Payment or honoraria for	None					
	lectures, presentations,						
	speakers bureaus,						
	manuscript writing or						
	educational events						
6	Payment for expert	None					
	testimony						
7	Support for attanding	Nana					
/	Support for attending meetings and/or travel	None					
	meetings and/or traver						
8	Patents planned, issued or pending	None					
9	Participation on a Data	None					
	Safety Monitoring Board or						
10	Advisory Board						
10	Leadership or fiduciary role in other board, society,	None					
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	Intellmed, s.r.o.	Co-founder of spin-off company. No relation to the				
	•		Manuscript.				
12	Receipt of equipment,	None					
	materials, drugs, medical						
	writing, gifts or other services						
13	Services Other financial or non-	None					
13	financial interests	None					

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133], Palacky University Olomouc [LF 2021_019], Technological Agency of the Czech Republic [TN01000013] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102) and Cancer Research Czech Republic. The author is co-founder of spin-off company Intellmed, Ltd., and Cancer Research Czech Republic Foundation with no relation to the Manuscript. Please place an "X" next to the following statement to indicate your agreement:

Date: March 30, 2022 Your Name: Marian Hajduch Manuscript Title: Cannabinoid receptor 2 expression in early stage non-small cell lung cancers identifies patients with good prognosis and longer survival Manuscript number (if known): TLCR-22-247

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials,	Ministry of Health of the Czech Republic [NV18-03- 00470]	Institutional funding		
	medical writing, article processing charges, etc.) No time limit for this item.	Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133]	Institutional funding		
		Palacky University Olomouc [LF 2021_019]	Institutional funding		
		Technological Agency of the Czech Republic [TN01000013]	Institutional funding		
		European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102)	Institutional funding		
		Cancer Research Czech Republic	Institutional funding		

	Time frame: past 36 months						
2	Grants or contracts from	None					
	any entity (if not indicated in item #1 above).						
3	Royalties or licenses	None					
3	Royalties of licenses						
4	Consulting fees	None					
5	Payment or honoraria for	None					
	lectures, presentations,						
	speakers bureaus,						
	manuscript writing or						
6	educational events Payment for expert	None					
0	testimony						
	cestimony						
7	Support for attending	None					
	meetings and/or travel						
8	Patents planned, issued or pending	None					
-							
9	Participation on a Data	None					
	Safety Monitoring Board or Advisory Board						
10	Leadership or fiduciary role	None					
10	in other board, society,						
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	Intellmed, s.r.o.	Founder of spin-off company. No relation to the				
			Manuscript.				
12	Receipt of equipment, materials, drugs, medical	None					
<u></u>							
	writing, gifts or other						
	services						
13	Other financial or non- financial interests	None					

The study was supported by institutional fundings by Ministry of Health of the Czech Republic [NV18-03-00470], Ministry of Education, Youth and Sport of the Czech Republic [LM2018125, LM2018133], Palacky University Olomouc [LF 2021_019], Technological Agency of the Czech Republic [TN01000013] and European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5102) and Cancer Research Czech Republic. The author is co-founder of spin-off company Intellmed, Ltd., and Cancer Research Czech Republic Foundation with no relation to the Manuscript. Please place an "X" next to the following statement to indicate your agreement: